Patrick James Doyle
President chez KINEMED INC
Profil
Patrick James Doyle is currently the Chief Executive Officer at Stelexis Therapeutics LLC and the President & Director at KineMed, Inc. He previously worked as the Chief Executive Officer at Ipsen Bioinnovation Ltd.
and held positions at CymaBay Therapeutics, Inc. and Roche Ltd.
He also worked as a Scientific Coordinator at Novo Nordisk, Inc. Dr. Doyle received his undergraduate and doctorate degrees from the University of Sunderland and his graduate degree from the University of Geneva.
Postes actifs de Patrick James Doyle
| Sociétés | Poste | Début |
|---|---|---|
| KINEMED INC | President | 22/05/2014 |
Stelexis Therapeutics LLC
 Stelexis Therapeutics LLC Pharmaceuticals: MajorHealth Technology Stelexis Therapeutics LLC focuses on identifying and isolating the earliest definable stem and progenitor cells, which harbor clonal properties and pre-cancerous alterations. The company was founded by Ulrich Steidl, Derrick Rossi, Amit Verma, Evripidis Gavathiotis, and Roman Perez-Soler in 2017 and is headquartered in New York ,NY. | Directeur Général | - |
Anciens postes connus de Patrick James Doyle
| Sociétés | Poste | Fin |
|---|---|---|
Ipsen Bioinnovation Ltd.
 Ipsen Bioinnovation Ltd. BiotechnologyHealth Technology Ipsen Bioinnovation Ltd. Engages in the research and development of pharmaceutical products. The company was founded in 2005 and is headquartered in Abingdon, the United Kingdom. | President | - |
Novo Nordisk, Inc.
 Novo Nordisk, Inc. BiotechnologyHealth Technology Novo Nordisk, Inc. operates diabetes care company. It offers biopharmaceuticals, chronic weight management, human growth hormone therapy and hemophilla management services. The firm also provides rare bleeding disorders, growth hormone related disorders, and women's health. The company was founded in 1982 and is headquartered in Plainsboro, NJ. | Corporate Officer/Principal | - |
Roche Ltd.
 Roche Ltd. Financial ConglomeratesFinance Roche Ltd. provides investment services. | Corporate Officer/Principal | - |
| CYMABAY THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Formation de Patrick James Doyle
| University of Sunderland | Doctorate Degree |
| University of Geneva | Graduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
Ipsen Bioinnovation Ltd.
Ipsen Bioinnovation Ltd. BiotechnologyHealth Technology Ipsen Bioinnovation Ltd. Engages in the research and development of pharmaceutical products. The company was founded in 2005 and is headquartered in Abingdon, the United Kingdom. | Health Technology |
CymaBay Therapeutics, Inc.
 CymaBay Therapeutics, Inc. BiotechnologyHealth Technology CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. Its products pipeline includes Seladelpar, MBX-2982, CB-0406, and CB-001. The company was founded on October 5, 1988 and is headquartered in Newark, CA. | Health Technology |
Roche Ltd.
Roche Ltd. Financial ConglomeratesFinance Roche Ltd. provides investment services. | Finance |
Novo Nordisk, Inc.
Novo Nordisk, Inc. BiotechnologyHealth Technology Novo Nordisk, Inc. operates diabetes care company. It offers biopharmaceuticals, chronic weight management, human growth hormone therapy and hemophilla management services. The firm also provides rare bleeding disorders, growth hormone related disorders, and women's health. The company was founded in 1982 and is headquartered in Plainsboro, NJ. | Health Technology |
KineMed, Inc.
 KineMed, Inc. Miscellaneous Commercial ServicesCommercial Services KineMed, Inc. develops and commercializes biomarker platform technology. It provides dynamic proteomics platform, a functionally interpretable systems biology platform. The company was founded by David M. Fineman and Marc K. Hellerstein in February 2001 and is headquartered in Emeryville, CA. | Commercial Services |
Stelexis Therapeutics LLC
Stelexis Therapeutics LLC Pharmaceuticals: MajorHealth Technology Stelexis Therapeutics LLC focuses on identifying and isolating the earliest definable stem and progenitor cells, which harbor clonal properties and pre-cancerous alterations. The company was founded by Ulrich Steidl, Derrick Rossi, Amit Verma, Evripidis Gavathiotis, and Roman Perez-Soler in 2017 and is headquartered in New York ,NY. | Health Technology |